Leukemia Clinical Trials

Showing 4881-4900 of 10,987 trials

A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (Goserelin Acetate Implant) 10.8 mg and ZOLADEX® (Goserelin Acetate Implant) 3.6 mg in Chinese Patients With Localized or Locally Advanced Hormonal Treatment -naïve Prostate Cancer

NCT03193060

This study is a multi-centre, prospective observational study. The study plans to enrol 500 patients with localized or locally advanced prostate cancer who are eligible and intended to be prescribed Zoladex® (goserelin acetate implant) 10.8 mg or Zoladex® (goserelin acetate implant) 3.6 mg as monotherapy or in combination with androgen blockade (CAB) at 50 clinical sites in China. The effectiveness and safety data will be collected at baseline and each visit within 26 weeks after treatment of Zoladex®.

Localized or Locally Advanced Prostate Cancer

AstraZeneca308 participantsStarted Sep 2017

Beijing, China • Beijing, China • Chengdu, China +22 more locations

COMPLETEDPhase 1

CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma

NCT03656705

The purpose of this clinical investigation is to evaluate the safety and effects of CCCR-modified NK92(CCCR-NK92)infusions in previously treated advanced non-small cell lung carcinoma(NSCLC).

Non-small Cell Lung Cancer

Henan Medical University2 participantsStarted Sep 2018

Xinxiang, Henan, China

A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (Goserelin Acetate Implant) 10.8 mg and ZOLADEX® (Goserelin Acetate Implant) 3.6 mg in Chinese Patients With Localized or Locally Advanced Hormonal Treatment -naïve Prostate Cancer

CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma

Related Searches

Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?

Conversational Agents to Improve Quality of Life in Palliative Care

Effects of a 24/7 Palliative Care Service Integration in a Metropolitan Area on Non-oncologic Patients

H19 in Acute Lymphoblastic Leukemia.

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

Relationship Between the Risk of Falls and Frailty, and the Effect of a Physical Exercise Program on These Conditions in the Elderly: a Randomized Crossover Clinical Trial.

A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)

Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker

Hepatobiliary Tumors Tissue Samples Acquisition

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Skin Tolerance of Medical Devices for Diabetes Monitoring and Treatment in Children With Type 1 Diabetes

The Efficacy of Speech Competition Training on Auditory Hallucination in Schizophrenia

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure

A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors